Forensic Analysis · General / Diversified · as of Sep 25, 2026
Bausch & Lomb Corp (BLCO)
A forensic read on Bausch & Lomb Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Grey Zone
Financial health
1.2
Distress distance
Clean
Earnings quality
3
Forensic signals
-35.2
P / E (ttm)
-5.6%
ROE
$6.1B
Market cap
0.00%
Dividend yield
6.5%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Bausch & Lomb Corp earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 1.2, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
0.8%
FY2025
Return on invested capital.Return on invested capital is 0.8% in the latest fiscal year and steady across FY2023–FY2025, inside a 0.4-point range. After-tax operating profit was $103M in FY2023 and $89M in FY2025, with operating income at 3.1% of revenue in FY2023, 3.4% in FY2024 and 2.2% in FY2025. The capital base behind it barely moved across FY2023–FY2025 ($11.6B to $11.7B, +2%), so there has been little new capital for that return to be earned on. FY2023's operating profit carried a $44M restructuring charge that took about 0.3 points off that year's return, and FY2025's carried a $58M restructuring charge that took about 0.4 points off the latest; so, net of each other, the two charges take about 0.1 points off the -0.1-point change across FY2023–FY2025.
87d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 78 to 87 days FY2024→FY2025 (receivables +19% vs revenue +6%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 74 → 78 → 87 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.
+0.5%/yr
FY2023–FY2025
Share count.Diluted share count changed +1% over the last 2 years to FY2025 (+0.5%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
Key fundamentals
Latest Revenue$5.10B
Revenue Growth YoY+6.5%
Revenue CAGR (2yr)+10.9%
Net Margin-7.1%
Free Cash Flow-$66.0M
Return on Equity-5.6%
Debt / Equity0.78x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bausch & Lomb Corp's actual 10-K/10-Q/8-K filings?